Is FDA-reviewed HRT safer than older HRT

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, today's FDA-reviewed hormone therapy products differ from older formulations in meaningful ways — including delivery methods, dose levels, and quality oversight standards. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

Why modern FDA-reviewed HRT differs from older HRT

Older HRT contained higher, less individualized doses. In the past, the most common estrogen was conjugated equine estrogen (CEE). It worked, but doses were larger and not individualized. According to FDA-approved prescribing information, higher estrogen doses may increase clot risk and side effects.

Current FDA-reviewed estrogen options include estradiol. Estradiol is structurally identical to human estrogen and may be used at lower, more physiologic doses. A qualified prescriber may determine whether this option is appropriate for an individual patient.

Modern delivery methods may affect risk profiles. According to the FDA-approved prescribing information for transdermal estradiol products, transdermal estrogen (patch, gel, spray) delivers estrogen through the skin directly into the bloodstream, bypassing the liver's first-pass metabolism — the step associated with production of clotting factors. According to FDA Drug Safety Communication, oral estrogen products carry boxed warnings regarding blood clot and stroke risk; transdermal formulations have a different risk profile that a qualified prescriber may discuss with you.

Progesterone options have also changed. For women with a uterus, progesterone protects the uterine lining. According to FDA-approved prescribing information, older synthetic progestins carry warnings regarding breast cancer and clot risk. Micronized progesterone, an FDA-reviewed commercially available option, has a distinct labeling profile; a qualified prescriber may assess which option is appropriate.

Modern FDA oversight ensures purity and consistency. According to FDA.gov, commercially available hormone therapy products must meet manufacturing, dosage, and absorption standards reviewed by the FDA before approval. This provides a level of quality assurance not present in older formulations or in compounded preparations, which are not subject to pre-dispensing FDA review for safety and effectiveness.

Practical takeaways

• According to NAMS, transdermal estradiol plus micronized progesterone may offer a more favorable risk profile for many women compared with older oral regimens — a qualified prescriber may evaluate your individual circumstances.
• According to FDA Drug Safety Communication, oral estrogen from older regimens carries boxed warnings for clot and stroke risk.
• Lower, standardized doses in current FDA-reviewed products may allow effective symptom management with a different risk profile than older, higher-dose therapies.
• Quality control standards for commercially available hormone therapy products today are governed by FDA manufacturing requirements not applied to compounded preparations.

In summary, modern FDA-reviewed hormone therapy products reflect decades of changes in dosing, delivery, and regulatory oversight compared to older formulations. According to ACOG, clinical decisions about hormone therapy — including which product and delivery method to use — should be made in consultation with a qualified prescriber based on individual health history and risk factors.